Company seeks to expand licence of Rinvoq (upadacitinib) in the US and EU to include treatment of adults with active psoriatic arthritis

Marketing application submissions for the new indication have been provided based on data from two Phase III studies (n=2,000 patients). In both studies, upadacitinib achieved non-inferiority versus adalimumab in terms of ACR20 response at week 12.